## Product datasheet for TL304298V

## GNB1L Human shRNA Lentiviral Particle (Locus ID 54584)

## Product data:

Product Type:
Product Name:
Locus ID:
Synonyms:
Vector:
Format:
Components:

RefSeq:
UniProt ID:
Summary:
shRNA Design:
shRNA Lentiviral Particles
GNB1L Human shRNA Lentiviral Particle (Locus ID 54584)
54584
DGCRK3; FKSG1; GY2; WDR14; WDVCF
pGFP-C-shLenti (TR30023)
Lentiviral particles
GNB1L - Human shRNA lentiviral particles (4 unique 29mer target-specific shRNA, 1 scramble control), 0.5 ml each, $>10 \wedge 7 \mathrm{TU} / \mathrm{ml}$.

NM 022446, NM 053004 NM 053004.1 $\underline{\text { NM 053004.2, BC012060 BC012060.1 NM } 053004.3}$ Q9BYB4

This gene encodes a G-protein beta-subunit-like polypeptide which is a member of the WD repeat protein family. WD repeats are minimally conserved regions of approximately 40 amino acids typically bracketed by gly-his and trp-asp (GH-WD), which may facilitate formation of heterotrimeric or multiprotein complexes. Members of this family are involved in a variety of cellular processes, including cell cycle progression, signal transduction, apoptosis, and gene regulation. This protein contains 6 WD repeats and is highly expressed in the heart. The gene maps to the region on chromosome 22q11, which is deleted in DiGeorge syndrome, trisomic in derivative 22 syndrome and tetrasomic in cat-eye syndrome. Therefore, this gene may contribute to the etiology of those disorders. Transcripts from this gene share exons with some transcripts from the C22orf29 gene. [provided by RefSeq, Jul 2008]
These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact techsupport@origene.com. If you need a special design or shRNA sequence, please utilize our custom shRNA service.

## Performance <br> Guaranteed:

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with $100 \%$ identity. One of the four constructs at minimum are guaranteed to produce $70 \%$ or more gene expression knock-down provided a minimum transfection efficiency of $80 \%$ is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at techsupport@origene.com. Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).

